

Supplementary Table SVII Association of *BRSK1* (rs1172822) (in LD with rs11668344) with reduced ovarian function and alkylating agents in VEVO discovery cohort.

Gene	Variant	Chrom	Ref.	Alt.	MAF	Model	Variant, interaction term	OR (95% CI)	P-value
<i>BRSK1</i>	rs1172822	19	C	T	0.35	1	Hormones	1.95 (0.98–3.91)	0.006
							rs1172822	0.63 (0.40–0.99)	0.045
							CED: 0	1 (ref)	0.001
							– >0–4000 mg/m ²	1.37 (0.63–2.98)	0.422
							– ≥4000–8000 mg/m ²	4.46 (1.83–10.87)	0.001
							– ≥8000 mg/m ²	4.71 (1.56–14.22)	0.006
						2	Hormones	0.59 (0.26–1.35)	0.069
							rs1172822	0.60 (0.26–1.35)	0.210
							CED: 0	1 (ref)	0.192
							– >0–4000 mg/m ²	1.73 (0.54–5.78)	0.357
							– ≥4000–8000 mg/m ²	5.11 (1.17–22.28)	0.030
							– ≥8000 mg/m ²	1.55 (0.36–6.66)	0.556
							SNP*CED: 0	1 (ref)	0.184
							– >0–4000 mg/m ²	0.74 (0.24–2.33)	0.610
							– ≥4000–8000 mg/m ²	0.88 (0.23–3.34)	0.852
							– ≥8000 mg/m ²	10.37 (0.95–113.13)	0.055

Alt, alternative allele; CED, cyclophosphamide equivalent dose; Chrom., chromosome; MAF, minor allele frequency; Ref, Reference allele; VEVO, DCOG-LATER VEVO cohort. Model 1: adjusted for principal components, hormone usage and CED score in four categories. Model 2: additional to Model 1 interaction term of variant*CED category.